Therapeutisch potentieel:
De FDA heeft 4 IL-6 monoklonale antilichamen goedgekeurd:
- Satralizumab
- Tocilizumab
- Siltuximab
- Sarilumab
Kunnen ze de mitochondriale functie herstellen bij Long COVID- en ME/CVS-patiënten?
De FDA heeft 4 IL-6 monoklonale antilichamen goedgekeurd:
- Satralizumab
- Tocilizumab
- Siltuximab
- Sarilumab
Kunnen ze de mitochondriale functie herstellen bij Long COVID- en ME/CVS-patiënten?
January 21, 2025 at 6:22 AM
Therapeutisch potentieel:
De FDA heeft 4 IL-6 monoklonale antilichamen goedgekeurd:
- Satralizumab
- Tocilizumab
- Siltuximab
- Sarilumab
Kunnen ze de mitochondriale functie herstellen bij Long COVID- en ME/CVS-patiënten?
De FDA heeft 4 IL-6 monoklonale antilichamen goedgekeurd:
- Satralizumab
- Tocilizumab
- Siltuximab
- Sarilumab
Kunnen ze de mitochondriale functie herstellen bij Long COVID- en ME/CVS-patiënten?
What is the efficacy & safety of the interleukin-6 receptor inhibitors #tocilizumab and #satralizumab in #MOGAD?
Aasim Ali & colleagues conducted a #SystematicReview and #MetaAnalysis to summarize the evidence:
journals.sagepub.com/doi/full/10....
Aasim Ali & colleagues conducted a #SystematicReview and #MetaAnalysis to summarize the evidence:
journals.sagepub.com/doi/full/10....
October 1, 2026 at 1:38 PM
What is the efficacy & safety of the interleukin-6 receptor inhibitors #tocilizumab and #satralizumab in #MOGAD?
Aasim Ali & colleagues conducted a #SystematicReview and #MetaAnalysis to summarize the evidence:
journals.sagepub.com/doi/full/10....
Aasim Ali & colleagues conducted a #SystematicReview and #MetaAnalysis to summarize the evidence:
journals.sagepub.com/doi/full/10....
New online! Satralizumab could reduce relapse risk in people with MOGAD
Satralizumab could reduce relapse risk in people with MOGAD
Nature Reviews Neurology, Published online: 06 May 2026; doi:10.1038/s41582-026-01219-6Treatment with the IL-6 receptor-blocking monoclonal antibody satralizumab is associated with a reduced risk of relapse in people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), according to new phase III trial data.
dlvr.it
May 7, 2026 at 1:59 AM
New online! Satralizumab could reduce relapse risk in people with MOGAD
FDA granted Priority Review to satralizumab for MOGAD, a rare autoimmune CNS disease. In trials, it reduced relapse risk by 68%. This could become the first disease-modifying treatment, a significant step forward for patients with limited options.
September 10, 2026 at 8:04 PM
FDA granted Priority Review to satralizumab for MOGAD, a rare autoimmune CNS disease. In trials, it reduced relapse risk by 68%. This could become the first disease-modifying treatment, a significant step forward for patients with limited options.
ICYMI: New online! Satralizumab could reduce relapse risk in people with MOGAD
Satralizumab could reduce relapse risk in people with MOGAD
Nature Reviews Neurology, Published online: 06 May 2026; doi:10.1038/s41582-026-01219-6Treatment with the IL-6 receptor-blocking monoclonal antibody satralizumab is associated with a reduced risk of relapse in people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), according to new phase III trial data.
dlvr.it
May 8, 2026 at 2:01 AM
ICYMI: New online! Satralizumab could reduce relapse risk in people with MOGAD
The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte glycoprotein antibody-associated disease. #AAN2026 https://www.medpagetoday.com/meetingcoverage/aan/120914
First Clinical Trial in MOGAD Meets Primary Endpoint
Satralizumab cuts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease
www.medpagetoday.com
April 24, 2026 at 8:50 PM
The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte glycoprotein antibody-associated disease. #AAN2026 https://www.medpagetoday.com/meetingcoverage/aan/120914
A new drug for MOGAD, a rare autoimmune disease attacking the central nervous system, reduced relapse risk by 68%. In trials, 87% of patients were relapse-free at 48 weeks vs 67% on placebo. This could be the first approved therapy.
U.S. FDA grants Priority Review for Roche's Enspryng for MOGAD, an autoimmune disease with no approv
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Roche's Enspryng (satralizumab) for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a rare autoimmun
www.biospace.com
September 11, 2026 at 8:04 PM
A new drug for MOGAD, a rare autoimmune disease attacking the central nervous system, reduced relapse risk by 68%. In trials, 87% of patients were relapse-free at 48 weeks vs 67% on placebo. This could be the first approved therapy.
🇹🇷 SGK’da SUT değişikliği: Tedavi ve ilaç ödeme şartları güncellendi
#Türkiye #Haber #Gündem #Sağlık #SGK #SUT #BirGün #Güncel
#Türkiye #Haber #Gündem #Sağlık #SGK #SUT #BirGün #Güncel
SGK’den kritik SUT değişikliği: Hangi tedavi ve ilaçların ödeme şartları değişti?
Sosyal Güvenlik Kurumu, Sağlık Uygulama Tebliği’nde organ ve doku nakillerinden meme kanseri tedavilerine, bronkoskopi ve kemik iliği nakli işlemlerinden bedeli ödenecek ilaçlara kadar birçok başlıkta değişiklik yaptı. Satralizumab için geri ödeme koşulları belirlenirken ilaç, yalnızca yatarak tedavide kullanılması halinde bedeli ödenecek ilaçlar listesine de eklendi.
www.birgun.net
October 2, 2026 at 4:11 AM
ICYMI: New online! Satralizumab could reduce relapse risk in people with MOGAD
Satralizumab could reduce relapse risk in people with MOGAD
Nature Reviews Neurology, Published online: 06 May 2026; doi:10.1038/s41582-026-01219-6Treatment with the IL-6 receptor-blocking monoclonal antibody satralizumab is associated with a reduced risk of relapse in people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), according to new phase III trial data.
dlvr.it
May 13, 2026 at 2:02 AM
ICYMI: New online! Satralizumab could reduce relapse risk in people with MOGAD
Exciting results in the clinical trial Plenary at #AANAM2026.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
April 21, 2026 at 4:08 PM
Exciting results in the clinical trial Plenary at #AANAM2026.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
the first positive phase 3 trial in MOGAD! satralizumab significantly reduced relapse rates in relapsing MOGAD compared to placebo with stable baseline open label immunosuppression allowed. IVSM use & MRI also favored satralizumab.
It’s a tough road to diagnosis when your own body starts attacking its CNS. MOGAD needs more awareness.
entechonline.com/mogad-sympto...
entechonline.com/mogad-sympto...
Satralizumab MOGAD Breakthrough: Scientists Cut Rare Brain Disease Relapses by 68%
Science and Technology Magazine to Explore Your Passion
entechonline.com
April 23, 2026 at 12:15 PM
It’s a tough road to diagnosis when your own body starts attacking its CNS. MOGAD needs more awareness.
entechonline.com/mogad-sympto...
entechonline.com/mogad-sympto...
Subcutaneous satralizumab demonstrates clinically meaningful improvements in proptosis, diplopia, and disease activity in patients with active or inactive thyroid eye disease, according to research published in Ophthalmology.
Learn more: https://bit.ly/4yWI3q4
#MedSky
Learn more: https://bit.ly/4yWI3q4
#MedSky
Satralizumab Improves Outcomes in Patients With Thyroid Eye Disease
Subcutaneous satralizumab improves proptosis, clinical activity, and diplopia in patients with active or inactive thyroid eye disease.
bit.ly
September 23, 2026 at 11:54 PM
Subcutaneous satralizumab demonstrates clinically meaningful improvements in proptosis, diplopia, and disease activity in patients with active or inactive thyroid eye disease, according to research published in Ophthalmology.
Learn more: https://bit.ly/4yWI3q4
#MedSky
Learn more: https://bit.ly/4yWI3q4
#MedSky
A step forward for MOGAD: FDA granted Priority Review to Enspryng® (satralizumab) — potentially the first MOGAD treatment. Trial: 68% lower relapse risk vs placebo. FDA decision expected Jan 10 2027.
https://www.gene.com/media/press-releases/15124/2026-09-09/us-fda-grants-priority-review-for-genent
https://www.gene.com/media/press-releases/15124/2026-09-09/us-fda-grants-priority-review-for-genent
September 10, 2026 at 7:16 PM
A step forward for MOGAD: FDA granted Priority Review to Enspryng® (satralizumab) — potentially the first MOGAD treatment. Trial: 68% lower relapse risk vs placebo. FDA decision expected Jan 10 2027.
https://www.gene.com/media/press-releases/15124/2026-09-09/us-fda-grants-priority-review-for-genent
https://www.gene.com/media/press-releases/15124/2026-09-09/us-fda-grants-priority-review-for-genent
💙 #MOGAD update: The FDA granted Priority Review to Genentech’s application for Enspryng® (satralizumab). In Phase III, it reduced relapse risk by 68%. If approved, it could be the first FDA-approved MOGAD treatment. Decision expected Jan. 10, 2027.
www.gene.com/media/press-...
www.gene.com/media/press-...
Genentech: Press Releases | U.S. FDA GRANTS PRIORITY REVIEW FOR GENENTECH’S ENSPRYNG FOR MOGAD, AN AUTOIMMUNE DISEASE WITH NO APPROVED TREATMENTS
The filing acceptance is based on positive results from the Phase III METEOROID study, which showed that Enspryng provided consistent, clinically meaningful improvements for people living with MOGAD.
www.gene.com
September 10, 2026 at 5:14 PM
💙 #MOGAD update: The FDA granted Priority Review to Genentech’s application for Enspryng® (satralizumab). In Phase III, it reduced relapse risk by 68%. If approved, it could be the first FDA-approved MOGAD treatment. Decision expected Jan. 10, 2027.
www.gene.com/media/press-...
www.gene.com/media/press-...
FDA Grants Priority Review to Roche's Enspryng for MOGAD
The U.S. Food and Drug Administration granted Priority Review to Genentech/Roche's supplemental Biologics License Application for Enspryn…
Read more: https://embers.news/article/fda-grants-priority-review-to-roches-enspryng-for-mogad-70337
The U.S. Food and Drug Administration granted Priority Review to Genentech/Roche's supplemental Biologics License Application for Enspryn…
Read more: https://embers.news/article/fda-grants-priority-review-to-roches-enspryng-for-mogad-70337
FDA Grants Priority Review to Roche's Enspryng for MOGAD
The U.S. Food and Drug Administration granted Priority Review to Genentech/Roche's supplemental Biologics License Application for Enspryng (satralizumab), positioning the therapy for a potential decision by January 10, 2027. If cleared, the medication would become the first approved disease-modifyin
embers.news
September 23, 2026 at 8:40 PM
FDA Grants Priority Review to Roche's Enspryng for MOGAD
The U.S. Food and Drug Administration granted Priority Review to Genentech/Roche's supplemental Biologics License Application for Enspryn…
Read more: https://embers.news/article/fda-grants-priority-review-to-roches-enspryng-for-mogad-70337
The U.S. Food and Drug Administration granted Priority Review to Genentech/Roche's supplemental Biologics License Application for Enspryn…
Read more: https://embers.news/article/fda-grants-priority-review-to-roches-enspryng-for-mogad-70337
European Medicines Agency validated Enspryng for MOGAD. Not an EMA approval.
https://europepharmatoday.com/news/roche-enspryng-satralizumab-mogad-ema-fda-september-2026?utm_source=bluesky&utm_medium=social&utm_campaign=roche-enspryng-satralizumab-mogad-ema-fda-september-2026
#EMA
https://europepharmatoday.com/news/roche-enspryng-satralizumab-mogad-ema-fda-september-2026?utm_source=bluesky&utm_medium=social&utm_campaign=roche-enspryng-satralizumab-mogad-ema-fda-september-2026
#EMA
September 14, 2026 at 5:57 AM
European Medicines Agency validated Enspryng for MOGAD. Not an EMA approval.
https://europepharmatoday.com/news/roche-enspryng-satralizumab-mogad-ema-fda-september-2026?utm_source=bluesky&utm_medium=social&utm_campaign=roche-enspryng-satralizumab-mogad-ema-fda-september-2026
#EMA
https://europepharmatoday.com/news/roche-enspryng-satralizumab-mogad-ema-fda-september-2026?utm_source=bluesky&utm_medium=social&utm_campaign=roche-enspryng-satralizumab-mogad-ema-fda-september-2026
#EMA
Friday desk: Enspryng MOGAD file validated at EMA. Not a CHMP opinion. Not a new EU MA.
https://europepharmatoday.com/news/roche-enspryng-satralizumab-mogad-ema-fda-september-2026?utm_source=bluesky&utm_medium=social&utm_campaign=roche-enspryng-satralizumab-mogad-ema-fda-september-2026
#EMA
https://europepharmatoday.com/news/roche-enspryng-satralizumab-mogad-ema-fda-september-2026?utm_source=bluesky&utm_medium=social&utm_campaign=roche-enspryng-satralizumab-mogad-ema-fda-september-2026
#EMA
September 11, 2026 at 6:04 AM
Friday desk: Enspryng MOGAD file validated at EMA. Not a CHMP opinion. Not a new EU MA.
https://europepharmatoday.com/news/roche-enspryng-satralizumab-mogad-ema-fda-september-2026?utm_source=bluesky&utm_medium=social&utm_campaign=roche-enspryng-satralizumab-mogad-ema-fda-september-2026
#EMA
https://europepharmatoday.com/news/roche-enspryng-satralizumab-mogad-ema-fda-september-2026?utm_source=bluesky&utm_medium=social&utm_campaign=roche-enspryng-satralizumab-mogad-ema-fda-september-2026
#EMA
Exciting times for thyroid eye disease. Our paper explores IL-6 receptor inhibition in TED.
www.aaojournal.org/article/S016...
www.aaojournal.org/article/S016...
Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials
To evaluate the primary efficacy and safety of satralizumab, an anti–interleukin-6
receptor antibody, in patients with thyroid eye disease (TED).
www.aaojournal.org
September 10, 2026 at 1:50 PM
Exciting times for thyroid eye disease. Our paper explores IL-6 receptor inhibition in TED.
www.aaojournal.org/article/S016...
www.aaojournal.org/article/S016...
Roche's satralizumab (Enspryng) just earned FDA Priority Review for MOGAD, a CNS autoimmune condition with no approved therapies. Decision expected January 2027.
Roche wins FDA Priority Review for Enspryng in MOGAD
The FDA has accepted Roche's sBLA for satralizumab in MOGAD, a CNS autoimmune disease with no approved treatments, with a decision due January 2027.
biotech.disruptsmedia.com
September 10, 2026 at 10:42 AM
Roche's satralizumab (Enspryng) just earned FDA Priority Review for MOGAD, a CNS autoimmune condition with no approved therapies. Decision expected January 2027.
This complex condition needs effective, accessible treatments and bespoke multidisciplinary care:
www.linkedin.com/posts/nimagh...
www.linkedin.com/posts/nimagh...
#ophthalmology #satralizumab #thyroideyedisease #ted #orbitalinflammation #ophthalmology #multidisciplinarycare #clinicalresearch #personalisedcare | Nima Ghadiri
An exciting time for thyroid eye disease: new treatments and care tailored to each patient
It's an exciting time. Our growing understanding of TED's biology is opening up new therapeutic possibiliti...
www.linkedin.com
September 10, 2026 at 1:50 PM
This complex condition needs effective, accessible treatments and bespoke multidisciplinary care:
www.linkedin.com/posts/nimagh...
www.linkedin.com/posts/nimagh...
Ophthopedia Update: Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials: To evaluate the primary efficacy and safety of satralizumab, an anti–interleukin-6 receptor antibody,… #Ophthalmology #ophthotwitter #eyecare
Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials
To evaluate the primary efficacy and safety of satralizumab, an anti–interleukin-6 receptor antibody, in patients with thyroid eye disease (TED).
dlvr.it
September 7, 2026 at 9:20 PM
Ophthopedia Update: Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials: To evaluate the primary efficacy and safety of satralizumab, an anti–interleukin-6 receptor antibody,… #Ophthalmology #ophthotwitter #eyecare
Satralizumab Market Trends & Growth Analysis 2035 - Wiseguy | WiseGuyReports www.wiseguyreports.com/reports/satr...
www.wiseguyreports.com
August 20, 2026 at 5:57 AM
Satralizumab Market Trends & Growth Analysis 2035 - Wiseguy | WiseGuyReports www.wiseguyreports.com/reports/satr...
Japan LS Aug 6: Chugai filed to expand satralizumab to MOGAD relapse prevention, set to be Japan's first MOGAD drug. Overseas: Alteogen-Biogen SC license up to $365m.
#Biogen #Chugai #LifeSciencesJapan
https://jlsweeklyen.substack.com/p/jlsw-daily-brief-august-6-2026-thu
#Biogen #Chugai #LifeSciencesJapan
https://jlsweeklyen.substack.com/p/jlsw-daily-brief-august-6-2026-thu
August 5, 2026 at 9:18 PM
Japan LS Aug 6: Chugai filed to expand satralizumab to MOGAD relapse prevention, set to be Japan's first MOGAD drug. Overseas: Alteogen-Biogen SC license up to $365m.
#Biogen #Chugai #LifeSciencesJapan
https://jlsweeklyen.substack.com/p/jlsw-daily-brief-august-6-2026-thu
#Biogen #Chugai #LifeSciencesJapan
https://jlsweeklyen.substack.com/p/jlsw-daily-brief-august-6-2026-thu
3/7 Three days prior, the company reported completion of Phase 3 trials in choroidal neovascularization secondary to pathologic myopia (faricimab) and thyroid eye disease (satralizumab).
August 4, 2026 at 1:41 PM
3/7 Three days prior, the company reported completion of Phase 3 trials in choroidal neovascularization secondary to pathologic myopia (faricimab) and thyroid eye disease (satralizumab).